CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 14,342 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $19.86, for a total value of $284,832.12. Following the completion of the transaction, the chief executive officer now directly owns 18,587 shares of the company’s stock, valued at $369,137.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CytomX Therapeutics, Inc. (CTMX) traded up $0.31 during trading hours on Friday, hitting $20.23. The company’s stock had a trading volume of 278,865 shares, compared to its average volume of 311,488.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.30). The company had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. analysts forecast that CytomX Therapeutics, Inc. will post -1.46 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Sean A. Mccarthy Sells 14,342 Shares of CytomX Therapeutics, Inc. (CTMX) Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/03/sean-a-mccarthy-sells-14342-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.

Several hedge funds have recently modified their holdings of CTMX. Wells Fargo & Company MN raised its position in shares of CytomX Therapeutics by 52.8% in the first quarter. Wells Fargo & Company MN now owns 22,424 shares of the biotechnology company’s stock worth $387,000 after buying an additional 7,747 shares in the last quarter. Swiss National Bank raised its position in shares of CytomX Therapeutics by 19.1% in the first quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock worth $463,000 after buying an additional 4,300 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of CytomX Therapeutics by 551.5% in the first quarter. JPMorgan Chase & Co. now owns 185,778 shares of the biotechnology company’s stock worth $3,208,000 after buying an additional 157,261 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of CytomX Therapeutics in the first quarter worth $485,000. Finally, American International Group Inc. raised its position in shares of CytomX Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,580 shares of the biotechnology company’s stock worth $217,000 after buying an additional 834 shares in the last quarter. Institutional investors own 60.02% of the company’s stock.

CTMX has been the subject of several recent analyst reports. Bank of America Corporation upped their target price on CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Nomura upped their target price on CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 8th. Finally, Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $31.88.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.